Crewe Advisors’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
Other funds holding LGND
Crewe Advisors's LGND Position: Q3 2026 in Review
Crewe Advisors increased its Ligand Pharmaceuticals (LGND) stake by 28% in Q3 2026, buying an estimated $7.69K and bringing the position to 120 shares worth $37.5K. The position accounts for ﹤0.01% of the portfolio, ranked #486.
Crewe Advisors first reported a position in LGND in Q2 2024 and has held it in 6 quarters since. 434 funds tracked by Wall St. Rank hold LGND as of Q3 2026.
- Crewe Advisors held 120 shares of Ligand Pharmaceuticals worth $37.5K as of Q3 2026.
- Crewe Advisors bought 26 Ligand Pharmaceuticals shares in Q3 2026, an estimated $7.69K.
- Ligand Pharmaceuticals made up ﹤0.01% of Crewe Advisors's portfolio in Q3 2026, its #486 holding.
- Crewe Advisors first reported a position in Ligand Pharmaceuticals in Q2 2024 and has held it in 6 quarters since.
- 434 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2026.
Based on Crewe Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.